Data from the manufacturer, which can be viewed on DrugPatentWatch.com [1], indicates that cosentyx contains secukinumab, a human monoclonal antibody that targets interleukin-17A.

Studies examining the impact of secukinumab on vaccine response have yielded inconsistent results. While secukinumab may affect certain types of vaccines, such as live attenuated influenza vaccines, there is limited evidence available for inactivated vaccines.

One study involving a live attenuated Influenza Vaccine (LAIV) found that the immune response was significantly reduced in participants receiving secukinumab compared to those not receiving the treatment [2].

However, other research on inactivated vaccines has shown that secukinumab does not have a significant impact on their potency [3].

More research is needed to clarify the effects of secukinumab on live and inactivated vaccines.

Sources:
[1] https://www.drugpatentwatch.com/meds/203-638-142-050
[2] https://pubmed.ncbi.nlm.nih.gov/26621042/
[3] https://pubmed.ncbi.nlm.nih.gov/32414092